<DOC>
	<DOCNO>NCT00503776</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Amifostine may decrease side effect cause chemotherapy radiation therapy . It yet know whether chemotherapy radiation therapy effective without amifostine treat head neck cancer . PURPOSE : This randomized phase II trial study amifostine see well work compare standard care reduce side effect patient undergo chemotherapy radiation therapy stage III stage IV head neck cancer .</brief_summary>
	<brief_title>Chemo/XRT +/- Amifostine Assess Outcomes Related Xerostomia , Mucositis , &amp; Dysphagia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare incidence severity acute chronic swallow dysfunction stage III IV head neck cancer patient receive concurrent chemoradiation without amifostine Secondary - To assess relative incidence severity acute chronic xerostomia stage III IV head neck cancer patient receive chemoradiation without amifostine . - To assess relative incidence severity mucositis mucositis-related inflammation stage III IV head neck cancer patient receive chemoradiation without amifostine . - To assess effect dysphagia , xerostomia , mucositis-related inflammation nutritional , physical , functional status OUTLINE : Patients undergo intensity-modulated radiotherapy ( IMRT ) concurrent chemotherapy comprise carboplatin paclitaxel weekly . Patients randomize 1 2 treatment arm . - Arm I ( standard care ) : Patients divide 1A 1B . - Arm IA : Standard care plus standardized nutrition therapy ( SNT ) - Arm IB : Standard care plus standardized nutrition therapy plus low weight resistance training ( LWRT ) . - Arm II ( amifostine ) : Patients divide 2A 2B . - Arm IIA : Amifostine 500mg dilute 2.9 ml inject 30-60 minute prior radiation dose plus standardized nutrition therapy - Arm IIB : Amifostine 500mg dilute 2.9 ml inject 30-60 minute prior radiation dose plus standardized nutrition therapy plus low weight resistance training In arm , patient undergo swallow function , dietary , body composition , muscle , physical functional performance measurement baseline 1 , 3 , 6 month post-therapy . Quality life , salivary production , fatigue , symptom ( include swallowing/eating food , appetite , weight loss/nutrition , pain , speech/communication ) assess baseline 1 , 3 , 6 month post-therapy . Anthropometric measurement also perform time point mid-therapy . Blood sample buccal rinse collect baseline 1 , 3 , 6 month post-therapy biomarker study proteomic genomic analysis liquid chromatography tandem mass spectrometry . After completion study treatment , patient follow 1 , 3 , 6 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Deglutition Disorders</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>Inclusion Criteria Age great 21 Biopsy proven stage 3 4 squamous cell carcinoma larynx , pharynx , oral cavity salivary glands No prior history active cancer within three year nonmelanoma skin cancer , early stage prostate early stage cervical cancer control comorbid disease ECOG PS 03 Plan definitive postoperative CCR within 4 week Written inform consent Working telephone May receive prior induction chemotherapy Agree use study supply liquid nutrition supplement dietary supplement , per o feeding tube intake Exclusion Criteria Diagnosed HIV AIDS History ETOH drug abuse within 3 month Pregnant lactate On steroid medication prescribe NSAIDs Consuming specialty nutrition supplement contain additional amount eicosapentaenoic acid ( EPA ) docosahexaenoic acid ( DHA ) On orexigenic ( appetite stimulant ) medication . Uncontrolled comorbid disease define : ) severe cardiac disease Class III great ; b ) blood pressure &gt; 160/95 ; c ) uncontrolled pain Does work telephone .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>xerostomia</keyword>
	<keyword>mucositis</keyword>
	<keyword>dysphagia</keyword>
	<keyword>radiation toxicity</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
</DOC>